- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04067050
A Clinical Study of the Comfilcon A Asphere Soft Contact Lens in Users of Digital Devices
March 17, 2021 updated by: CooperVision, Inc.
A Clinical Study of the Biofinity Energys Soft Contact Lens in Users of Digital Devices
The aim of this work is to investigate the clinical performance and subjective acceptance of the comfilcon A asphere contact lens when compared to single-vision spectacles in subjects who have never worn contact lenses and who use digital devices (such as phones, tablets, laptops, desktop computers) for at least 4 hours per day on at least 5 days per week.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The aim of this clinical work is to compare the clinical performance and subjective acceptance of comfilcon A asphere contact lens when compared to single-vision spectacles in subjects who use digital devices (phones, tablets, laptops, desktop computers) for at least 4 hours per day on at least 5 days per week.
Subjects will be randomized to use either their habitual spectacles or the study contact lenses for two months.
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Manchester, United Kingdom, M13 9PL
- Eurolens Research - The University of Manchester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 31 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- They are between 18 and 35 years of age (inclusive).
- They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent.
- They are willing and able to follow the protocol.
- They are a 'neophyte' (i.e. someone who has not worn contact lenses previously, with the exception for the purposes of a trial fitting, lasting up to one week).
- They have a contact lens spherical prescription between -1.00 to -6.25D (inclusive) based on the ocular refraction.
- They have a cylindrical correction of -0.875DC or less in each eye based on the ocular refraction
- They own and habitually wear single vision spectacles used for both distance and near vision, including computer and digital device use.
- Their single vision spectacles have a mean sphere equivalent within ±0.50D of that of the refraction found in the study for each eye (after having taken lens effectivity into account).
- They are willing to be fitted with contact lenses and understand they may be randomized to either group.
- They are willing to wear the contact lenses (if relevant) or spectacles for at least 8 hours per day, 5 days per week.
- They typically use digital devices for a minimum of 4 hours per day, 5 days per week.
- They agree not to change the spectacles they will wear for digital device use for the duration of the study.
- They agree not to participate in other clinical research for the duration of the study.
Exclusion Criteria:
- They have an ocular disorder which would normally contra-indicate contact lens wear.
- They have a systemic disorder which would normally contra-indicate contact lens wear.
- They are using any topical medication such as eye drops (including comfort drops) or ointment on a regular basis.
- The spectacles they use for digital device viewing on the study have been made with specialist features for computer use, digital eye fatigue or are multifocal/bifocal.
- They are aphakic.
- They have had corneal refractive surgery.
- They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
- They are pregnant or breastfeeding.
- They have any infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or they have any immunosuppressive disease (e.g. HIV), or a history of anaphylaxis or severe allergic reaction.
- They have evidence of a heterotropia or decompensating heterotropia on cover test.
- They have a history of having been prescribed prism in their spectacles (by self report).
- They have taken part in any other contact lens or care solution clinical trial or research, within two weeks prior to starting this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: comfilcon A asphere
Subjects will wear their comfilcon A asphere contact lenses for two months.
Lenses will be worn on a daily wear, reusable basis for at least 8 hours per day, 5 days per week.
|
Contact Lens
Other Names:
|
|
Active Comparator: Habitual Spectacles
Subjects will wear their single vision habitual spectacles for two months for at least 8 hours per day, 5 days per week.
|
Habitual spectacles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptom of Burning
Time Frame: Baseline
|
Symptom of burning measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Burning
Time Frame: 1 month
|
Symptom of burning measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
1 month
|
|
Symptom of Burning
Time Frame: 2 months
|
Symptom of burning measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
2 months
|
|
Symptom of Itching
Time Frame: Baseline
|
Symptom of itching measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Itching
Time Frame: One Month
|
Symptom of itching measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Itching
Time Frame: Two Months
|
Symptom of itching measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Feeling of Foreign Body
Time Frame: Baseline
|
Symptom of feeling of foreign body measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Feeling of Foreign Body
Time Frame: One Month
|
Symptom of feeling of foreign body measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Feeling of Foreign Body
Time Frame: Two Months
|
Symptom of feeling of foreign body measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Tearing
Time Frame: Baseline
|
Symptom of tearing measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Tearing
Time Frame: One Month
|
Symptom of tearing measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Tearing
Time Frame: Two Months
|
Symptom of tearing measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Excessive Blinking
Time Frame: Baseline
|
Symptom of excessive blinking measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Excessive Blinking
Time Frame: One Month
|
Symptom of excessive blinking measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Excessive Blinking
Time Frame: Two Months
|
Symptom of excessive blinking measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Eye Redness
Time Frame: Baseline
|
Symptom of eye redness measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Eye Redness
Time Frame: One Month
|
Symptom of eye redness measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Eye Redness
Time Frame: Two Months
|
Symptom of eye redness measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Eye Pain
Time Frame: Baseline
|
Symptom of eye pain measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Eye Pain
Time Frame: One Month
|
Symptom of eye pain measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Eye Pain
Time Frame: Two Months
|
Symptom of eye pain measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Heavy Eyelids
Time Frame: Baseline
|
Symptom of heavy eyelids measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Heavy Eyelids
Time Frame: One Month
|
Symptom of heavy eyelids measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Heavy Eyelids
Time Frame: Two Months
|
Symptom of heavy eyelids measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Dryness
Time Frame: Baseline
|
Symptom of dryness measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Dryness
Time Frame: One Month
|
Symptom of dryness measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Dryness
Time Frame: Two Months
|
Symptom of dryness measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Blurred Vision
Time Frame: Baseline
|
Symptom of blurred vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Blurred Vision
Time Frame: One Month
|
Symptom of blurred vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Blurred Vision
Time Frame: Two Months
|
Symptom of blurred vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Double Vision
Time Frame: Baseline
|
Symptom of double vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Double Vision
Time Frame: One Month
|
Symptom of double vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Double Vision
Time Frame: Two Months
|
Symptom of double vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Difficulty Focusing For Near Vision
Time Frame: Baseline
|
Symptom of difficulty focusing for near vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Difficulty Focusing For Near Vision
Time Frame: One Month
|
Symptom of difficulty focusing for near vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Difficulty Focusing For Near Vision
Time Frame: Two Months
|
Symptom of difficulty focusing for near vision measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Increased Sensitivity to Light
Time Frame: Baseline
|
Symptom of increased sensitivity to light measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Increased Sensitivity to Light
Time Frame: One Month
|
Symptom of increased sensitivity to light measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Increased Sensitivity to Light
Time Frame: Two Months
|
Symptom of increased sensitivity to light measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Colored Haloes Around Objects
Time Frame: Baseline
|
Symptom of colored haloes around objects measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Colored Haloes Around Objects
Time Frame: One Month
|
Symptom of colored haloes around objects measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Colored Halos Around Objects
Time Frame: Two Months
|
Symptom of colored halos around objects measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Feeling That Sight is Worsening
Time Frame: Baseline
|
Symptom of feeling that sight is worsening measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Feeling That Sight is Worsening
Time Frame: One Month
|
Symptom of feeling that sight is worsening measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Feeling That Sight is Worsening
Time Frame: Two Months
|
Symptom of feeling that sight is worsening measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
|
Symptom of Headache
Time Frame: Baseline
|
Symptom of headache measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Baseline
|
|
Symptom of Headache
Time Frame: One Month
|
Symptom of headache measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
One Month
|
|
Symptom of Headache
Time Frame: Two Months
|
Symptom of headache measured by frequency on a scale of 0-2 (0-never, 1- occasionally, 2- often/always) and intensity on a scale of 1-2 (1- moderate 2- intense).
|
Two Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 4, 2019
Primary Completion (Actual)
February 28, 2020
Study Completion (Actual)
March 30, 2020
Study Registration Dates
First Submitted
August 21, 2019
First Submitted That Met QC Criteria
August 21, 2019
First Posted (Actual)
August 26, 2019
Study Record Updates
Last Update Posted (Actual)
April 13, 2021
Last Update Submitted That Met QC Criteria
March 17, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EX-MKTG-105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ametropia
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedRefractive AmetropiaUnited States
-
European Vision Institute Clinical Research NetworkCompletedNormal Subjects, AmetropiaSpain
-
Alcon ResearchCompletedMyopia | Hyperopia | Refractive AmetropiaUnited States
-
Bausch & Lomb IncorporatedCompletedRefractive AmetropiaUnited States
-
Alcon ResearchCompletedRefractive AmetropiaUnited States
-
Bausch & Lomb IncorporatedCompletedRefractive AmetropiaUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedRefractive AmetropiaUnited States
-
Unicon Optical Co. Ltd.Recruiting
Clinical Trials on comfilcon A asphere
-
CooperVision, Inc.Completed
-
CooperVision International Limited (CVIL)Centre for Ocular Research & Education, CanadaRecruiting
-
CooperVision, Inc.CompletedAstigmatism | MyopiaUnited States
-
CooperVision, Inc.CompletedPresbyopiaUnited States
-
CooperVision, Inc.CompletedPresbyopiaUnited States
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.; Foresight Regulatory Strategies, Inc.CompletedRefractive Error
-
CooperVision, Inc.CompletedMyopiaUnited States, United Kingdom